Porcine Epidemic Diarrhea Vaccines Global Market Report 2024

Porcine epidemic diarrhea (PED) vaccines are formulated to confer immunity against the porcine epidemic diarrhea virus (PEDV), which causes severe gastrointestinal illness in pigs. These vaccines play a crucial role in preventing and managing outbreaks of Porcine Epidemic Diarrhea, thereby safeguarding the health and productivity of pig populations and ensuring the economic stability of the swine industry.

The primary types of porcine epidemic diarrhea vaccines are live vaccines and killed vaccines. Live vaccines contain attenuated or weakened forms of the PEDV virus. They are utilized in diverse settings, including piglets and adult pigs, across veterinary hospitals and hog production farms.

The porcine epidemic diarrhea vaccines market research report is one of a series of new reports that provides porcine epidemic diarrhea vaccines market statistics, including porcine epidemic diarrhea vaccines industry global market size, regional shares, competitors with a porcine epidemic diarrhea vaccines market share, detailed porcine epidemic diarrhea vaccines market segments, market trends, and opportunities, and any further data you may need to thrive in the porcine epidemic diarrhea vaccines industry. This porcine epidemic diarrhea vaccines research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The porcine epidemic diarrhea vaccines market size has grown strongly in recent years. It will grow from $1.56 billion in 2023 to $1.67 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historical period can be attributed to factors such as large-scale vaccination campaigns, expanded immunization programs (EPI), the adoption of disposable syringes, efforts to eradicate diarrhea, and initiatives such as the global alliance for vaccines and immunization (GAVI).

The porcine epidemic diarrhea vaccines market size is expected to see strong growth in the next few years. It will grow to $2.25 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be credited to increased emphasis on immunization programs, expansion of vaccine development pipelines, growing pig populations, focus on cold chain management, and rising awareness about the importance of preventive healthcare measures. Major trends anticipated during this period include ongoing innovations in vaccine delivery device technology, a shift towards needle-free solutions, advancements in personalized medicine, increasing preference for self-administered vaccines, and improvements in animal healthcare infrastructure and distribution networks.

The growth of the porcine epidemic diarrhea vaccines market is expected to be driven by the increasing prevalence of pig farming. Pig farming encompasses various activities such as raising domestic pigs for meat production, breeding, managing from birth to market weight, and marketing pork products. This rise in pig farming is attributed to global demand for pork, advancements in breeding and management practices, technological improvements in farming techniques, and expanding pork consumption markets. Porcine epidemic diarrhea (PED) vaccines play a crucial role in preventing and managing outbreaks in pig farming. Typically administered through injection or orally during the sow's gestation period, these vaccines confer passive immunity to newborn piglets via colostrum. As of December 2023, the United States Department of Agriculture reported approximately 75 million hogs and pigs on American farms, underscoring the significant role of pig farming in boosting the demand for PED vaccines.

Leading companies in the porcine epidemic diarrhea vaccines sector are focusing on innovation to strengthen their market positions. One notable development is the introduction of the porcine parvovirus (PPV) vaccine, designed to prevent reproductive failures in pigs caused by PPV. Boehringer Ingelheim launched the ReproCyc ParvoFLEX vaccine in March 2022, which offers comprehensive protection against infertility, stillbirths, mummified fetuses, and weak piglets resulting from PPV. This innovative vaccine underscores the company's commitment to enhancing the health and productivity of pig herds through advanced formulation and efficacy.

In September 2021, Vaxxinova International BV acquired Newport Laboratories from Boehringer Ingelheim, aiming to bolster its position in the animal health industry. Newport Laboratories specializes in custom-made vaccines for swine and cattle, aligning with Vaxxinova's goal to expand its portfolio of vaccines and diagnostic products, particularly in the swine sector. Newport Laboratories is a US-based company that manufactures custom-made vaccines for swine and cattle.

Major companies operating in the porcine epidemic diarrhea vaccines market are Zoetis Inc., Merck Animal Health, Elanco Animal Health, Idexx Laboratories Inc., Bio-Rad Laboratories Inc., Ceva Santé Animale Health Company, Phibro Animal Health Corporation, Benchmark Animal Health Ltd., IDT Biologika GmbH, Vaxxinova, Qilu Animal Health Products Factory Co. Ltd., Tecnovax, Green Cross Veterinary Products Co. Ltd., Nisseiken Co. Ltd., Komipharm International Co. Ltd., Boehringer Ingelheim Animal Health, MSD Animal Health, Ourofino Saúde Animal, Medgene Labs, Harrisvaccines Inc.

Asia-Pacific was the largest region in the porcine epidemic diarrhea vaccines market in 2023. The regions covered in the porcine epidemic diarrhea vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the porcine epidemic diarrhea vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The porcine epidemic diarrhea vaccines market consists of sales of ingelvac PEDV, barricade, PED vax, PEDV shield, and enterisol ileitis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.